Abstract
NF-κB essential modulator (NEMO), the non-catalytic regulatory subunit of the IκB kinase (IKK) complex, is essential for the canonical NF-κB activation pathway. It has been identified as a molecular platform for assembling the IKK complex and recruiting upstream IKK activators. However, the exact mechanism for regulating IKK activity has still remained elusive. This review describes structural and functional characteristics of NEMO protein, covers the feasible polyubiquitin-mediated NEMO-dependent IKK complex activation mechanism, and briefly summarizes some proteins that bind to NEMO for enhancing or suppressing IKK complex activity. Furthermore, it also discusses several bioactive compounds that disrupt the protein-protein interactions (PPI) involving NEMO, as these PPI may act as alternative routes to develop novel pharmacological agents for inflammation and cancer therapy.
Keywords: IKKγ/NEMO, IKK activation model, K63-linked polyubiquitin chains, linear polyubiquitin chains, NEMO-binding domain (NBD), oligomerzation states, protein-protein interactions.
Current Drug Targets
Title:Insights into Targeting NEMO for Pharmacological Regulation
Volume: 15 Issue: 9
Author(s): Hong-Xi Chu, Jun-Feng Zhu, Jing-Jie Huang, Zheng-Yu Jiang, Meng-Chen Lu, Xiao-Jin Zhang, Hao-Peng Sun and Qi-Dong You
Affiliation:
Keywords: IKKγ/NEMO, IKK activation model, K63-linked polyubiquitin chains, linear polyubiquitin chains, NEMO-binding domain (NBD), oligomerzation states, protein-protein interactions.
Abstract: NF-κB essential modulator (NEMO), the non-catalytic regulatory subunit of the IκB kinase (IKK) complex, is essential for the canonical NF-κB activation pathway. It has been identified as a molecular platform for assembling the IKK complex and recruiting upstream IKK activators. However, the exact mechanism for regulating IKK activity has still remained elusive. This review describes structural and functional characteristics of NEMO protein, covers the feasible polyubiquitin-mediated NEMO-dependent IKK complex activation mechanism, and briefly summarizes some proteins that bind to NEMO for enhancing or suppressing IKK complex activity. Furthermore, it also discusses several bioactive compounds that disrupt the protein-protein interactions (PPI) involving NEMO, as these PPI may act as alternative routes to develop novel pharmacological agents for inflammation and cancer therapy.
Export Options
About this article
Cite this article as:
Chu Hong-Xi, Zhu Jun-Feng, Huang Jing-Jie, Jiang Zheng-Yu, Lu Meng-Chen, Zhang Xiao-Jin, Sun Hao-Peng and You Qi-Dong, Insights into Targeting NEMO for Pharmacological Regulation, Current Drug Targets 2014; 15 (9) . https://dx.doi.org/10.2174/1389450115666140804215119
DOI https://dx.doi.org/10.2174/1389450115666140804215119 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology Molecular Imaging Probe Development Using Microfluidics
Current Organic Synthesis Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Cytotoxic and Chemopreventive Effects of Gemin D Against Different Mutagens Using In Vitro and In Vivo Assays
Anti-Cancer Agents in Medicinal Chemistry Effect of HAART on Salivary Composition and Oxidative Profile in HIVInfected Patients
Current HIV Research Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design